Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Interpace Biosciences, Inc. (OTCMKTS:IDXG)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.68 and traded as high as $1.7030. Interpace Biosciences shares last traded at $1.7022, with a volume of 6,886 shares traded.

Interpace Biosciences Trading Up 0.6%

The firm has a market cap of $7.31 million, a P/E ratio of -33.00 and a beta of 0.59. The stock’s fifty day moving average is $1.82 and its two-hundred day moving average is $1.69.

Interpace Biosciences (OTCMKTS:IDXG) last posted its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.The company had revenue of $9.03 million during the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.